Navigation Links
New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
Date:6/30/2008

inaccuracies of our analysis with respect to the TRIUMPH-1 preliminary trial results and market opportunity; and the inability of ourselves and our suppliers to manufacture ITRE and the nebulizers used to administer the drug in accordance with all applicable regulatory requirements and in sufficient quantity to support patient demand. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and current reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward- looking statements. We are providing this information as of June 30, 2008, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. [uthr-g]


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)
2. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
3. Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications
4. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
5. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
6. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
7. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
8. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
9. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
10. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
11. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), a ... a non-invasive, wireless continuous glucose monitoring system, today announced ... Interim CEO of Echo Therapeutics, will present at "TEN", ... Mr. Doman will make a corporate presentation ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... to anti-clotting drug, CHICAGO, March 29 ... dose of a medication that prevents blood clotting,significantly ... coronary interventions (PCI), according to a multicenter study,reported ... the SCAI,Annual Scientific Sessions in Partnership with ACC ...
... ,culotte, technique better?, CHICAGO, March 29 When ... of two coronary arteries -- or a,bifurcation lesion -- ... vessels without blocking the opening to the side branch. ... on which of,two techniques produces the best long-term results ...
Cached Medicine Technology:Tailored Clopidogrel Dosing Improves PCI Outcomes 2Tailored Clopidogrel Dosing Improves PCI Outcomes 3Stenting Techniques Vie in Branchpoint Lesions 2
(Date:4/14/2014)... Doctors at Henry Ford Hospital reached a medical ... replacement using a novel way to access the heart. ... United States performing the unique procedure called transcaval valve ... blood vessels. , Northern Michigan resident Viola Waller, 80, ...
(Date:4/14/2014)... , , Penicillin, one of the scientific marvels of the ... it once won against bacterial infections. But scientists at ... new approach to restoring its combat effectiveness, even against ... the power of the penicillin family of drugs since ...
(Date:4/14/2014)... their radiation treatment decisions leaves cancer patients feeling more ... distress around the experience, researchers from the Perelman ... report in the journal Cancer . , In ... Neha Vapiwala, MD , an associate professor in the ...
(Date:4/14/2014)... Popular web information on colorectal cancer is too ... address the appropriate risks to and concerns of patients, ... , In a review of a dozen popular websites, ... cancer screening were written beyond the recommended sixth-grade reading ...
(Date:4/14/2014)... the molecule, called microRNA 135b, is a vital ,worker, ... growth of bowel cancers. , Drugs targeted at the ... mutations at once, while tests for it could identify ... , The research was carried out by an international ...
Breaking Medicine News(10 mins):Health News:Henry Ford Hospital hits new heart valve surgery milestone 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 3Health News:Shared decision making during radiation therapy improves patient satisfaction 2Health News:Shared decision making during radiation therapy improves patient satisfaction 3Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3Health News:'MicroRNA' could be key target for bowel cancer treatment 2
... French . , Montreal, February 22, 2010 ... young immigrants. A new study published in the Journal ... children from multiethnic, disadvantaged, inner-city neighbourhoods are up to 3.5 ... an estimated 45,000 school-aged children immigrate to Canada with their ...
... URBANA - A University of Illinois researcher advises caution ... this country,s Latino adolescents and young adults. "When ... in a 90-minute program, the Latino students in my classes ... were right!" said Marcela Raffaelli, a U of I professor ...
... ... Boehringer Ingelheim (Canada) Ltd. , ... Toronto, Ontario, Canada (PRWEB) February 22, 2010 -- Dalton Pharma Services announces ... the agreement Dalton will continue to provide chemistry services in support of Boehringer,s pharmaceutical ...
... life, researchers say , MONDAY, Feb. 22 (HealthDay News) ... causes low energy levels and reduced quality of life, ... a new study suggests. , About 15 percent of ... late side effect of chemotherapy or radiation therapy. , ...
... ... ... ... ...
... , ... ... ... ...
Cached Medicine News:Health News:Are Latino teens sexual risk takers? It's complicated, researcher says 2Health News:Are Latino teens sexual risk takers? It's complicated, researcher says 3Health News:Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement 2Health News:Testicular Cancer Survivors May Have Hormone Deficiency 2Health News:Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World 2Health News:Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World 3Health News:Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World 4Health News:Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World 5Health News:Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World 6Health News:57 Year-Old Grandmother Travels to Atacama Desert to Run First of Four Ultramarathons for Charity 2Health News:57 Year-Old Grandmother Travels to Atacama Desert to Run First of Four Ultramarathons for Charity 3Health News:57 Year-Old Grandmother Travels to Atacama Desert to Run First of Four Ultramarathons for Charity 4Health News:57 Year-Old Grandmother Travels to Atacama Desert to Run First of Four Ultramarathons for Charity 5Health News:57 Year-Old Grandmother Travels to Atacama Desert to Run First of Four Ultramarathons for Charity 6
... , , The Shortyavailable with both Impact ... our face-to-face relationship with the scientific community generates ... pipetting easier and more effective., Shorter and ... Gets you closer to the working area ...
... Powerful and Flexible Impact And Impact2 Pipettors ... volume ranges, our single channel Impact and ... of any application. Engineered with the same ... multichannel line, these pipettors are equally easy ...
... And Impact2 Pipettors , , Available ... channel Impact and Impact2 pipettors can effectively ... with the same ergonomic design and superior ... are equally easy to program for a ...
... The Finnpipette BioControl is a ... technology. A complete liquid handling system ... twelve interchangeable tip cone modules. All ... tip cone modules fit one handle. ...
Medicine Products: